Graduada de la Universidad Complutense de Madrid (2003), la Dra. Arenas trabajó durante varios años en el Hospital Clínico Veterinario de la UCM y en la Universidad Alfonso X el Sabio, donde también ejerció como profesora de Medicina Interna. En 2011 obtuvo el doctorado por la UCM con su estudio sobre enfermedades adrenales caninas y, posteriormente, en 2012, se trasladó a Reino Unido para trabajar en el sector de la clínica privada.
También realizó una residencia, avalada por el Colegio Europeo de Medicina Interna (ECVIM), en la Universidad de Cambridge. Posteriormente, también trabajó en el hospital de referencia Willows Veterinary Specialist de Solihull (Birmingham).
Publicaciones científicas de contacto:
Corsini A, Niessen S, Miceli D, Caney S, Zeugswetter F, Sieber-Ruckstuh N, Arenas C, Fleeman L, O Leal R, Battellino M & Fracassi F. Quality of life and response to treatment in cats with hypersomatotropism: the owners’ point of view. Journal of Feline Medicine and Surgery. 2022 Aug;24(8):e175-e182. doi: 10.1177/1098612X221098718.
Jesus L, Arenas C, Domínguez-Ruiz M,Silvestrini P, Ryane. Englar E, Roura X, Oliveira Leal R. Xanthinuria secondary to allopurinol treatment in dogs with leishmaniosis: Current perspectives of the Iberian veterinary community. Comparative Immunology, Microbiology and Infectious Diseases 83 (2022) 101783https://doi.org/10.1016/j.cimid.2022.101783
García San Jose P, Arenas C, Alonso Miguel D, Gónzalez S, Clares M, Portero M & Pérez Alenza MD. Survival of dogs with pituitary-dependent hyperadrenocorticism treated twice daily with low doses of trilostane. Vet Rec. 2022;e1630. doi.org/10.1002/vetr.1630
Rebocho R, Domínguez-Ruiz M,. Englar RE, Arenas C, Pérez-Alenza MD, Corsini A, Fracassi F, Bennaim M & Oliveira Leal R. Use of Deoxycorticosterone Pivalate by Veterinarians: A Western European Survey. Vet. Sci. 2021, 8, 271. https://doi.org/10.3390/vetsci8110271
Changes in systolic blood pressure in dogs with pituitary dependent hyperadrenocorticism during the first year of trilostane treatment" JVIM. 2020. 1-12. DOI: 10.1111/jvim.15978
Arenas C, Pérez Alenza MD, García San Jose P, Llauet L, Pérez C, Melian C & Feldman E. "Assesment of laboratory monitoring of trilostane treatment in dogs with pituitary dependent hyperadrenocorticism" JVIM. 2020. 1-10. DOI: 10.1111/jvim.15830
García San Jose P, Arenas C, Clares M, Cuesta P & Pérez Alenza MD. "Prevalence of hypertension and risk factors associated in dogs with spontaneous hyperadrenocorticism" JVIM. 2020. 1-11. DOI: 10.1111/jvim.15841
O Cathasaigh, M; Arenas, C; Ortiz, A; Hall, J; Rudorf, H. "Primary Ureteral Urothelial (Transitional Cell) Carcinoma in a Boxer dog.". Veterinary Record Case Reports. 2018. doi: 10.1136/vetreccr-2018-000607
Arenas C, Pérez-Alenza MD, Granados Soler JL and Peña L. Adjuvant therapy for highly malignant canine mammary tumours: Cox-2 inhibitor versus chemotherapy. A case-control prospective study. Vet Record. 2016. Jul 30; 179 (5):125
Salgüero R, Arenas C and Herrtage M. Bilateral perinephric pseudocysts in a cat. Salgüero R, Arenas C and Herrtage M. Vet Rec Case Rep. 2015. 3
Arenas C, Melián C and Pérez-Alenza MD. Long-term survival of dogs with adrenal-dependent hyperadrenocorticism: a comparison between mitotane and twice daily trilostane treatment. JVIM.2014; 28: 473-480
Arenas C, Pérez Alenza MD and Melián C. Clinical features, outcome and prognostic factors in dogs diagnosed with non cortisol-secreting adrenal tumors without surgically intervention: 21 cases (1994-2009). Vet Rec. 2013, 173: 501
Arenas C, Melián C and Pérez-Alenza MD. Evaluation of two trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: BID versus SID. JVIM 2013; 27: 1478-1485
Clemente M, Andrés PJ, Arenas C, Melián C, Morales M, Pérez-Alenza MD. Comparison of non-selective adrenocorticolysis with mitotane or trilostane for the treatment of dogs with pituitary-dependent hyperadrenocorticism. Vet Rec. 2007 Dec 15;161(24):805-9.
Pérez-Alenza MD, Arenas C, Lopez ML, Melian C. Long-term efficacy of trilostane administered twice daily in dogs with pituitary-dependent hyperadrenocorticism. J Am Anim Hosp Assoc. 2006 Jul-Aug;42(4):269-76.
POSTERS Y COMUNICACIONES EN CONGRESOS NO INCLUIDAS
PUBLICACIONES NACIONALES NO INCLUIDAS
MIEMBRO DE LA JUNTA DIRECTIVA DEL ESVE (EUROPEAN SOCIETY OF VETERINARY ENDOCRINOLOGY)
